Wuhan Kaide Jinuo Biotechnology

Kindgen (Wuhan Kaide Jinuo Biotechnology) is a clinical-stage biotechnology company based in Wuhan, China, specializing in the development of innovative gene therapies for rare genetic disorders and oncology. The company utilizes a proprietary adeno-associated virus (AAV) vector platform to design and manufacture high-potency genetic medicines. Its lead programs, KD-001 for Hemophilia B and KD-002 for Hemophilia A, have both entered clinical development, representing significant milestones in the Chinese gene therapy landscape. Kindgen aims to provide one-time curative treatments for patients with high unmet medical needs by leveraging its integrated R&D and large-scale GMP manufacturing capabilities. The company is a key player in the Wuhan East Lake High-tech Development Zone (Biolake) biotech cluster.